Research programme: autoimmune disease therapeutics - Toleranzia

Drug Profile

Research programme: autoimmune disease therapeutics - Toleranzia

Alternative Names: multiple sclerosis tolerogen; myasthenia gravis tolerogen; rheumatoid arthritis tolerogen; TOL 1; TOL 2; type 1 diabetes mellitus tolerogen

Latest Information Update: 08 Nov 2016

Price : $50

At a glance

  • Originator Toleranzia
  • Class Proteins
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Myasthenia gravis
  • Research Multiple sclerosis; Rheumatoid arthritis; Type 1 diabetes mellitus

Most Recent Events

  • 01 Nov 2016 Toleranzia has patent protection for its tolerogenic platform in USA
  • 31 Oct 2016 Toleranzia applies for Orphan Drug status for TOL 2 in Myasthenia gravis in USA
  • 21 Oct 2016 Toleranzia and Hellenic Pasteur Institute agree to co-develop TOL 2 for Myasthenia gravis before October 2016 (9206447; 9206424)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top